TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
TriSalus Life Sciences, Inc. (TLSI)
Company Research
Source: Business Wire
Reported revenues of $5.7 million in 4Q23, up 77% over prior yearFull year revenues of $18.5 million, up 49% over prior yearGross Margin of 90% in 4Q23 and 86% for full yearCMS reimbursement granted for the TriNav® Infusion System via assignment of an HCPCS codeReal-world data published on TriNav system demonstrating significant improvement in the delivery of therapeutics to liver tumors for patients with higher disease burdenReceived 510k clearance of TriNav Large and TriGuide systemsCompleted enrollment in phase 1 clinical trials (100 patients) in several liver indications; data will be analyzed in the second half of 2024Initiated first-in-man clinical trial of its novel pancreatic infusion technology (510k cleared), plus nelitolimod, to demonstrate safety and efficacy DENVER & SALT LAKE CITY--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced its financial results for the fourth quarter and full year ended December 31, 2023, and provided a business upd
Show less
Read more
Impact Snapshot
Event Time:
TLSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSI alerts
High impacting TriSalus Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
TLSI
News
- TriSalus Reports Q1 2024 Financial Results and Business UpdateBusiness Wire
- TriSalus Life Sciences, Inc. (NASDAQ: TLSI) is now covered by analysts at Jonestrading. They set a "buy" rating and a $16.00 price target on the stock.MarketBeat
- TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of DirectorsBusiness Wire
- TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference CallBusiness Wire
- TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth InitiativesBusiness Wire